Humanin Peptide Evidence and Clinical Trial Status

No clinical trial has ever administered humanin peptide to human participants in a registered study. At Longevity Benchmark, we evaluate peptide research against registered clinical trial records and regulatory filings so readers can separate tested medical therapies from experimental laboratory compounds.

A search of federal trial databases reveals seven human studies involving the molecule. Every single project measures endogenous humanin as an observational biomarker in blood or tissue. Because no trial administers the molecule, no human efficacy data, safety profiles, or clinical dosing guidelines exist.

Does Humanin Peptide Work? What the Human Record Shows

Humanin peptide has no proven therapeutic effect in humans because no completed or active clinical trial has ever administered it to human participants. A search of the federal database at ClinicalTrials.gov returns seven human studies. In every one of those seven studies, researchers evaluate endogenous humanin strictly as an observational biomarker in blood or tissue samples.

None of those trials evaluate whether taking humanin peptide treats any disease, alters body composition, or influences healthspan. Two of the seven registered studies use an interventional design, but neither administers humanin. One study tests structured high-intensity exercise, while the other investigates anaesthetic drug combinations during renal surgery.

Without human administration trials, claims regarding benefits remain entirely unverified. There is no human efficacy data, no adverse-event record, and no validated clinical outcome associated with humanin supplementation. Commercial marketing that describes humanin as a tested therapy contradicts the clinical record.

Registered Clinical Trial Parameters for Humanin

The seven human studies catalogued on the federal clinical trial registry evaluate humanin strictly as a diagnostic or prognostic biomarker across kidney disease, cardiac surgery, reproductive conditions, and physical disability. In five of these studies, investigators use observational cohort designs to track natural circulating levels in specific patient populations.

In the remaining two interventional protocols, humanin serves as an outcome measure rather than the tested therapeutic agent. For example, study NCT07678073 evaluates whether different anaesthesia protocols influence post-operative humanin levels. The interventions are sevoflurane general anaesthesia and bupivacaine with morphine, not humanin peptide.

Similarly, study NCT07438002 tests an exercise routine in dialysis patients, measuring endogenous humanin in blood before and after physical activity. The entire federal registry contains zero interventional protocols testing exogenous humanin peptide administration.

Absence of Established Dosage and Commercial Protocol Origins

There is no established human dose, therapeutic window, or safe administration schedule for humanin peptide. Because humanin has never entered a human trial as an investigational drug, medical science has established no quantitative dose.

Consumers encounter dosing protocols and cycle guidelines on internet forums and commercial supplier websites. These published schedules are entirely ungrounded in human trial data. Any dosing schedule found online is not derived from clinical trial evidence.

Similarly, there are no documented side effect profiles or safety boundaries from human clinical investigations. The absence of reported adverse events in registries reflects a total absence of clinical administration, not a clean safety record. No price for humanin peptide is published in any source this review could verify. Our page on peptide therapy cost reports medication at $150 to $400 per month as checked in October 2026, but those figures describe clinic-supplied peptide therapy as a category and are not humanin prices.

The Inconsistent Direction of Human Biomarker Data

Circulating humanin levels do not follow a consistent direction across human diseases, which invalidates the common commercial premise that higher levels are universally beneficial. Online vendors market humanin by claiming that circulating concentrations decline with advancing chronological age. However, clinical studies measuring serum humanin across diverse patient cohorts demonstrate conflicting patterns.

In oncology and acute infection, elevated humanin tracks with active pathology. A clinical investigation by Mohamed and colleagues in Discover Oncology (PMID 41518474, DOI 10.1007/s12672-025-04325-x) evaluated 75 breast cancer patients and 70 age-matched healthy controls. Serum humanin was significantly higher in the cancer cohort than in controls (p < 0.001).

Similarly, Zhong and colleagues reported in Pathogens (DOI 10.3390/pathogens15090966) that serum humanin was significantly higher in 20 patients with hypervirulent Klebsiella pneumoniae infection than in 20 matched healthy controls (p < 0.001). In the opposite direction, Suliman and colleagues reported reduced mitochondrial-derived peptide levels in 160 adults with advanced kidney failure compared with 80 controls (Antioxidants, DOI 10.3390/antiox15080956), and Dagli and colleagues reported reduced serum humanin in gestational diabetes (Upsala Journal of Medical Sciences, DOI 10.48101/ujms.v131.14142).

Cardiovascular Risk and the Lack of Clinical Reference Ranges

A study of chronic haemodialysis patients demonstrates why targeting a specific humanin level is clinically impossible. Bolignano and colleagues investigated 83 haemodialysis patients with a mean age of 67 years in Cardiorenal Medicine (PMID 41849628, DOI 10.1159/000551517). The researchers identified a curvilinear association between circulating humanin and cardiovascular events.

In that cohort, both unusually low and unusually high humanin concentrations correlated with elevated cardiovascular risk. Adding humanin values improved the prognostic accuracy of standard cardiovascular risk models. Because risk increased at both extremes of the distribution, simply increasing humanin could theoretically push individuals into a higher risk bracket.

Currently, clinical medicine recognizes no validated reference range, therapeutic window, or target level for circulating humanin. Without standardized reference intervals, a measured value cannot indicate health or disease. This clinical ambiguity mirrors the research status we outline in our review of BPC-157 clinical research.

Federal Regulatory and Compounding Status

Humanin peptide has no regulatory approval from the Food and Drug Administration (FDA) and has never been reviewed for pharmaceutical compounding. On its public docket regarding bulk drug substances that may present significant safety risks, the FDA maintains specific categories for compounded substances.

Certain experimental peptides appear on the FDA Category 2 list due to safety concerns, including growth hormone releasing peptide-2, growth hormone releasing peptide-6, ipamorelin acetate, and kisspeptin-10. Other nominated peptides were formally withdrawn by their nominators. Those withdrawn substances include BPC-157, CJC-1295, dihexa acetate, emideltide (DSIP), epitalon, GHK-Cu, KPV, MOTS-c, and thymosin alpha-1.

Humanin appears nowhere on the FDA compounding docket. It is absent from the Category 2 list and the list of withdrawn nominations. This absence means no agency has assessed humanin for compounding risk. It does not signify regulatory clearance, safety approval, or clinical authorization. We detail federal regulatory classifications in our guide to peptide therapy FDA status.

Biological Classification and the MOTS-c Comparison

Humanin is a mitochondrial-derived peptide, also classified as a mitochondrial microprotein. Unlike classical peptide hormones transcribed from nuclear DNA, humanin is encoded directly within the mitochondrial genome. Researchers frequently abbreviate humanin as HN. Synthetic peptide analogues have also been developed for laboratory investigation, most notably HNG.

Scientists study humanin alongside other mitochondrial-encoded microproteins, such as SHMOOSE. This biological class also includes MOTS-c. However, humanin and MOTS-c occupy fundamentally different stages of clinical development. While both originate from mitochondrial DNA, their human clinical evidence profiles are not comparable.

As documented in our evaluation of MOTS-c peptide evidence, MOTS-c is currently evaluated in an interventional Phase 2a trial (NCT07505745). That randomized, double-blind trial enrolled a target of 120 adults and administers MOTS-c via subcutaneous injection for prediabetes. In sharp contrast, humanin has zero interventional administration trials on record.

Dietary Patterns and Lifestyle Association Studies

Published human studies evaluating humanin in relation to lifestyle factors are small, cross-sectional, and do not demonstrate that altering humanin improves clinical outcomes. In Frontiers in Nutrition (volume 12, DOI 10.3389/fnut.2025.1727012, PMID 41883858), Vicinanza and colleagues examined 49 elderly patients with non-valvular atrial fibrillation. We examined this pilot in our report on mitochondrial microproteins and the Mediterranean diet.

That cross-sectional pilot found that higher adherence to a Mediterranean diet correlated with higher serum humanin (p = 0.045) and higher SHMOOSE (p = 0.046). Humanin also correlated inversely with the oxidative-stress marker sNox2-dp (rho = -0.335, p = 0.019). However, cross-sectional correlations in 49 elderly cardiovascular patients cannot establish causality or demonstrate therapeutic efficacy.

Similarly, physical activity does not reliably alter humanin concentrations across age brackets. Horwath and colleagues examined resting and post-exercise humanin across young adults with cerebral palsy, typically developing adults, and adolescents (PMID 42349896, DOI 10.1113/ep093298). Resting humanin was comparable across cohorts, and exercise elicited negligible changes. Readers exploring systemic health metrics can review our analysis of what biological age measures.

Conditions Required to Alter the Evidence Assessment

Revising our evidence assessment for humanin peptide requires substantial advancements in formal clinical trials and diagnostic standardization. Before clinicians can consider humanin a viable therapeutic agent, researchers must initiate registered Phase 1 and Phase 2 interventional trials. These trials must directly administer standardized humanin or its analogues to human participants.

Investigators must publish comprehensive pharmacokinetic, pharmacodynamic, and safety data. Efficacy endpoints must demonstrate objective improvements in disease states compared against placebo controls. Furthermore, clinical laboratories must establish validated diagnostic assays with standardized reference intervals for endogenous humanin.

Until randomized clinical trials demonstrate reproducible clinical benefits and acceptable safety profiles, humanin remains an unproven experimental molecule. Patients should consult licensed healthcare providers to discuss evidence-based interventions backed by completed clinical trials.

Clinical Trial and Literature Sources

This evidence review is grounded directly in public clinical trial registries, regulatory dockets, and peer-reviewed biomedical literature accessed in October 2026. The primary sources evaluating humanin peptide include:

Clinical registry entries: NCT06105229, NCT06125249, NCT03431844, NCT04104958, NCT05506228, NCT07438002, and NCT07678073 accessed via ClinicalTrials.gov.

Regulatory records: United States Food and Drug Administration, Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks docket, accessed October 2026.

Peer-reviewed studies: Mohamed MH et al. (Discover Oncology, PMID 41518474); Suliman ME et al. (Antioxidants, DOI 10.3390/antiox15080956); Bolignano D et al. (Cardiorenal Medicine, PMID 41849628); Zhong Y et al. (Pathogens, DOI 10.3390/pathogens15090966); Dagli S et al. (Upsala Journal of Medical Sciences, DOI 10.48101/ujms.v131.14142); Shen A et al. (American Journal of Translational Research, DOI 10.62347/ifrp1860); Horwath O et al. (Experimental Physiology, PMID 42349896); and Vicinanza R et al. (Frontiers in Nutrition, PMID 41883858).

Frequently Asked Questions

What is humanin peptide?

Humanin is a mitochondrial-derived peptide, or mitochondrial microprotein, encoded directly within mitochondrial DNA rather than nuclear DNA. It is often abbreviated as HN in scientific literature, while synthetic analogues appear under names such as HNG. In human clinical research, humanin is studied primarily as a circulating biomarker in blood and tissue across cardiovascular, metabolic, and renal conditions. It has no approved clinical indications and has not been administered as a therapeutic agent in registered human trials.

Is humanin a peptide?

Yes, humanin is a peptide. Specifically, it belongs to a unique subclass of short signaling proteins known as mitochondrial-derived peptides (MDPs) or mitochondrial microproteins. Unlike standard human peptide hormones, which are encoded by genes located in the cell nucleus, humanin is encoded directly within mitochondrial DNA. Other microproteins originating from mitochondrial DNA include SHMOOSE and MOTS-c. While structurally classified as a peptide, it remains an investigational molecule without approved medical applications.

Does humanin peptide work?

There is no scientific proof that humanin peptide works as a therapeutic agent in humans. As of October 2026, ClinicalTrials.gov lists seven clinical studies involving humanin, and all seven evaluate it strictly as an observational biomarker in blood or tissue. Zero registered trials have administered humanin peptide to human participants. Without interventional clinical trials testing humanin against a placebo, researchers have no human efficacy data, clinical outcome metrics, or verified health benefits. Claims that humanin improves human longevity, metabolism, or muscle function are clinically unsupported.

What is the dosage for humanin peptide?

There is no established clinical dosage, therapeutic window, or administration schedule for humanin peptide. Because humanin has never entered human interventional trials as a drug product, no medical organization has published a verified dose. Dosing protocols circulated online are not derived from clinical trial evidence.

Does humanin peptide have side effects?

The human side effect profile of humanin peptide is entirely unknown because no clinical trial has ever administered the compound to human participants. The absence of reported adverse events in scientific literature reflects a total lack of human administration trials, not evidence of safety. Furthermore, observational biomarker data indicate that elevated circulating humanin correlates with severe bacterial infections and breast cancer, while a study of 83 haemodialysis patients recorded more cardiovascular events at both low and high humanin levels. The physiological consequences of administering humanin remain unstudied.

Is humanin peptide FDA approved?

Humanin peptide is not approved by the Food and Drug Administration (FDA) for any medical diagnosis, treatment, or clinical application. There are no approved pharmaceutical products containing humanin on the market. In addition, humanin does not appear on FDA bulk drug substance compounding dockets. It is absent from the FDA Category 2 list of substances presenting significant safety risks and absent from the list of nominated and withdrawn compounding substances. This absence means compounding authorities have never formally assessed humanin.

What are the benefits of humanin peptide?

Published scientific literature has demonstrated no verified therapeutic benefits from humanin peptide supplementation in humans. While researchers study natural endogenous humanin as a biomarker that fluctuates in response to disease, diet, and physiological stress, taking synthetic humanin has never been tested in human clinical trials. Commercial marketing promoting humanin for fat loss, cognitive enhancement, anti-aging, or muscle growth relies on unverified laboratory extrapolations rather than human clinical evidence. Registered clinical trials show zero completed human therapeutic evaluations.

Humanin vs MOTS-c: what is the difference?

Humanin and MOTS-c are both mitochondrial-derived peptides encoded within mitochondrial DNA, but they occupy completely different stages of human clinical investigation. Humanin has seven registered clinical studies on ClinicalTrials.gov, every one of which measures it purely as an observational biomarker without administering the peptide. In contrast, MOTS-c is the subject of an active, randomized, double-blind Phase 2a interventional drug trial (NCT07505745) testing subcutaneous administration in 120 adults with prediabetes. MOTS-c has advanced into human drug testing, while humanin remains an unadministered laboratory biomarker.

Related

• MOTS-c Peptide Clinical Evidence and Phase 2a Trial Status
• Peptide Therapy FDA Status and Compounding Restrictions
• Peptide Therapy Cost Factors and Monthly Clinic Pricing
• BPC-157 Research Evidence and Federal Regulatory Review
• Mediterranean Diet Pilot on Mitochondrial Microproteins
• What Biological Age Testing Measures and Clinical Validity